SCN1A and Dravet syndrome: A series of ASOs have been designed to target nonproductive alternative splicing sites in SCN1A mRNA in a DS mouse model to inhibit nonsense-mediated decay and increase the expression of productive SCN1A mRNA and Nav.1.1 (Figure 2D) [27].